IO Biotech to explore strategic alternatives including merger, sale, or liquidation

IO Biotech, Inc.

Company to evaluate merger, business combination, sale of assets, or liquidation and dissolution.
Further reduction-in-force and cost-cutting measures are also under consideration.
No timetable for the process; no assurance any transaction will occur.
IO Biotech (Nasdaq: IOBT) is a clinical-stage cancer vaccine developer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.